Related Experiment Video
Updated: Jun 29, 2025
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants
Tikvah K Hayes1,2,3, Elisa Aquilanti1,2, Nicole S Persky2,4,5
1Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA.
Abstract:
The epidermal growth factor receptor, EGFR, is frequently activated in lung cancer and glioblastoma by genomic alterations including missense mutations. The different mutation spectra in these diseases are reflected in divergent responses to EGFR inhibition: significant patient benefit in lung cancer, but limited in glioblastoma. Here, we report a comprehensive mutational analysis of EGFR function. We perform saturation mutagenesis of EGFR and assess function of ~22,500 variants in a human EGFR-dependent lung cancer cell line. This approach reveals enrichment of erlotinib-insensitive variants of known and unknown significance in the dimerization, transmembrane, and kinase domains. Multiple EGFR extracellular domain variants, not associated with approved targeted therapies, are sensitive to afatinib and dacomitinib in vitro. Two glioblastoma patients with somatic EGFR G598V dimerization domain mutations show responses to dacomitinib treatment followed by within-pathway resistance mutation in one case. In summary, this comprehensive screen expands the landscape of functional EGFR variants and suggests broader clinical investigation of EGFR inhibition for cancers harboring extracellular domain mutations.
Insights
This study comprehensively screened epidermal growth factor receptor (EGFR) variants, identifying new mutations sensitive to targeted therapies. Findings suggest broader clinical investigation for EGFR-targeted drugs in various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal growth factor receptor (EGFR) is frequently altered in lung cancer and glioblastoma.
- Genomic alterations in EGFR lead to differential responses to EGFR inhibitors between lung cancer and glioblastoma.
- Understanding the functional landscape of EGFR mutations is crucial for developing effective targeted therapies.
Purpose of the Study:
- To perform a comprehensive mutational analysis of EGFR function.
- To identify novel EGFR variants and their sensitivity to targeted therapies.
- To explore the clinical relevance of EGFR extracellular domain mutations.
Main Methods:
- Saturation mutagenesis of EGFR was performed.
- ~22,500 EGFR variants were assessed for function in an EGFR-dependent lung cancer cell line.
- Functional analysis included assessing sensitivity to EGFR inhibitors like erlotinib, afatinib, and dacomitinib.
Main Results:
- Enrichment of erlotinib-insensitive EGFR variants was observed in dimerization, transmembrane, and kinase domains.
- Multiple EGFR extracellular domain variants showed sensitivity to afatinib and dacomitinib in vitro.
- Two glioblastoma patients with EGFR G598V mutations responded to dacomitinib, with one developing resistance.
Conclusions:
- The comprehensive screen expands the understanding of functional EGFR variants.
- EGFR extracellular domain mutations may represent a target for afatinib and dacomitinib.
- Broader clinical investigation of EGFR inhibition is warranted for cancers with extracellular domain mutations.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
